Gerald Clarke | 11/27/2013
There have been some high profile cases of antibodies causing severe reactions, as well as posing a high risk to patients, these late stage failures are hugely costly. Is there a way to prevent or predict these immune reactions to biologics? We spoke to Harald Kropshofer Senior Personalized Healthcare Leader, Pharmaceutical Development F. Hoffman La Roche about his work on whole blood assays to assess cytokine response and t cell dependant responses and how these can be integrated into the drug...
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
DigIT Pharma AI Commercial Excellence & Health 2026
September 9 - 11, 2026
Berlin, Germany
Register Now |
View Agenda |
Learn More